Literature DB >> 15795698

Early development of immunity in diGeorge syndrome.

Anna Sedivá1, Jiøina Bartůnková, Radana Zachová, Andrea Poloucková, Ondrej Hrusák, Ales Janda, Eduard Kocárek, Drahuse Novotná, Kamila Novotná, Tibor Klein.   

Abstract

BACKGROUND: diGeorge syndrome is a relatively common congenital disorder with developmental defects, including hypoplasia or pathologic migration of the thymus, associated with deletion of contiguous genes on chromosome 22. We prospectively followed a cohort of children with confirmed 22q11.2 deletion. MATERIAL/
METHODS: One to six repeated examination were performed in 13 boys and 21 girls, age 4 days to 19 years. Due to the proposed role of the thymus in T lymphocyte selection, we studied T lymphocytes and their function, and also the presence of double positive CD4+CD8+ and gamma/delta T lymphocytes in peripheral blood.
RESULTS: A low number of T lymphocytes was detected in the majority of patients before the age of 2 years. Both spontaneous and PHA-induced proliferation were unexpectedly higher than in normal samples from children <2 years old. Both T cell numbers and function normalized thereafter in the majority of patients. Double positive T cells were detected in one boy, together with transient positivity of antinuclear antibodies. Gamma/delta T cells were greater than 5% in 21% of the children. In our 5-year prospective study we have not yet observed serious clinical signs of immunodeficiency or autoimmunity in these patients, except for repeated respiratory infections.
CONCLUSIONS: All patients classified as partial diGeorge syndrome presented with delayed but gradual development of immune function against a background of impaired support by the thymus.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15795698

Source DB:  PubMed          Journal:  Med Sci Monit        ISSN: 1234-1010


  8 in total

1.  Hypocalcaemia in a patient with congenital heart disease.

Authors:  L A McCusker; N P Jenkins; J E Hancock
Journal:  J R Soc Med       Date:  2007-01       Impact factor: 5.344

2.  Secondary immunologic consequences in chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome).

Authors:  R Zemble; E Luning Prak; K McDonald; D McDonald-McGinn; E Zackai; K Sullivan
Journal:  Clin Immunol       Date:  2010-05-15       Impact factor: 3.969

3.  Resolution of Primary Immune Defect in 22q11.2 Deletion Syndrome.

Authors:  Yiwa Suksawat; Achara Sathienkijkanchai; Jittima Veskitkul; Orathai Jirapongsananuruk; Nualanong Visitsunthorn; Pakit Vichyanond; Punchama Pacharn
Journal:  J Clin Immunol       Date:  2017-04-20       Impact factor: 8.317

Review 4.  Immunological aspects of 22q11.2 deletion syndrome.

Authors:  A R Gennery
Journal:  Cell Mol Life Sci       Date:  2011-10-09       Impact factor: 9.261

5.  Persistent low thymic activity and non-cardiac mortality in children with chromosome 22q11.2 microdeletion and partial DiGeorge syndrome.

Authors:  P Eberle; C Berger; S Junge; S Dougoud; E Valsangiacomo Büchel; M Riegel; A Schinzel; R Seger; T Güngör
Journal:  Clin Exp Immunol       Date:  2008-11-24       Impact factor: 4.330

6.  Maturational alterations of peripheral T cell subsets and cytokine gene expression in 22q11.2 deletion syndrome.

Authors:  Y Kanaya; S Ohga; K Ikeda; K Furuno; T Ohno; H Takada; N Kinukawa; T Hara
Journal:  Clin Exp Immunol       Date:  2006-04       Impact factor: 4.330

Review 7.  Candidemia in children after complex congenital heart defects surgery treated with caspofungin--our own experience and a review of literature.

Authors:  Radoslaw Jaworski; Ninela Irga; Ireneusz Haponiuk; Maciej Chojnicki; Elzbieta Arlukowicz; Mariusz Steffek; Mariusz Sroka; Katarzyna Gierat-Haponiuk; Jacek Juscinski; Lucyna Palkowska; Aneta Sendrowska; Wojciech Kosiak
Journal:  Med Sci Monit       Date:  2011-05

8.  The TREC/KREC assay for the diagnosis and monitoring of patients with DiGeorge syndrome.

Authors:  Eva Froňková; Adam Klocperk; Michael Svatoň; Michaela Nováková; Michaela Kotrová; Jana Kayserová; Tomáš Kalina; Petra Keslová; Felix Votava; Hana Vinohradská; Tomáš Freiberger; Ester Mejstříková; Jan Trka; Anna Sedivá
Journal:  PLoS One       Date:  2014-12-08       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.